Trial Profile
A Phase 1 Multicenter, Open-label, Dose-escalation Trial of MBC-11, an Etidronate-ara-C Conjugate in Patients With Malignant Tumors With Cancer-induced Bone Disease (CIBD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2020
Price :
$35
*
At a glance
- Drugs Cytarabine/etidronic acid (Primary)
- Indications Bone metastases
- Focus Adverse reactions; First in man
- Sponsors Osteros Biomedica
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 01 Jun 2017 According to a an Osteros Biomedica media release, results from this study will be presented at the ASCO conference 2017.
- 01 Feb 2016 Status changed from recruiting to completed as per ClinicalTrials.gov record.